of Galcanezumab in Patients With COVID-19
disease 2019 is an infectious respiratory disease caused by
SARS-CoV-2, previously referred to as "2019 novel
Lilly and Company has not studied the use of galcanezumab in patients
should use their clinical judgment in determining the most
appropriate approach in treating a patient with galcanezumab who has
confirmed or suspected COVID-19.
mAbs Have no Direct Specific Immunomodulatory Effect
CGRP mAbs have been engineered to bind to either the CGRP peptide or
receptor with high specificity and minimized interaction with the
As CGRP is not an immune system target, CGRP mAbs have no direct
use of galcanezumab is not associated with increased risk of
infections or immunosuppression, nor are such events identified as
important risks in the galcanezumab risk management plan.6
Literature Related to Use of CGRP Monoclonal Antibody Therapy in a
Patient With COVID-19
is limited published literature on the management of patients with
migraine and COVID-19. As of the last revision date, the Spanish
Society of Neurology's Headache Study Group has published their
opinion that the currently available data do not suggest that
interruption to standard headache therapies is warranted.7
In an editorial published in Headache, the authors recommend
the use of migraine preventive therapies, which include CGRP mAbs,
that allow for management of the patient in a telehealth setting.8
the most current information regarding the coronavirus, please refer
to the WHO website:
Coronavirus disease (COVID-19) outbreak
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed November 10, 2020.
Coronavirus. World Health Organization. Accessed November 10, 2020.
Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus
on calcitonin gene-related peptide for prophylactic migraine therapy.
Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what
headache specialists need to know. Headache.
Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for
the use of monoclonal antibodies in migraine. Headache.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Morollón N, Belvís R, De Dios A, et al. Standard
headache and neuralgia treatments and SARS-CoV-2: opinion of the
Spanish Society of Neurology's Headache Study Group. Neurología.
Szperka CL, Ailani J, Barmherzig R, et al. Migraine care in the era
of COVID-19: clinical pearls and plea to insurers. Headache.
= calcitonin gene-related peptide
= coronavirus disease 2019
= monoclonal antibody
= severe acute respiratory syndrome coronavirus 2
= World Health Organization
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.